Significant A1C Difference Achieved of Once-Daily Lantus® Plus Oral Therapy Comp

New data demonstrated that people with type 2 treated with the LANTUS® plus oral antidiabetic medications achieve greater blood glucose control, defined as reaching target A1C= 7%, with less risk of hypoglycemia compared to standard twice-daily premixed insulin and no oral agents. The study included 364 people with type 2 diabetes who were previously inadequately controlled on oral agents and had never been treated with insulin. Patients were either treated with LANTUS® once-daily injection while continuing oral therapy (Amaryl® [glimepiride TABLETS] or another sulfonylurea plus metformin), or discontinued oral agents and received a twice-daily injection of premixed 70% NPH insulin and 30% regular insulin. Fifty percent more patients in the LANTUS® plus orals treated group achieved target glycemic control (A1C £7%) without having an episode of nocturnal hypoglycemia, compared to those on premixed insulin and no oral medications (p = 0.0013).

“These data confirm that adding basal insulin glargine to oral therapy can help physicians and their patients more safely and effectively restore glycemic control in type 2 diabetes, with significantly less hypoglycemia than twice-daily premixed insulin,” said Hans Uwe Janka, M.D., the lead investigator and Professor of Medicine and Head of Section of Internal Medicine at the Central Hospital Bremen-Nord, Bremen, Germany.

“With just one injection and one blood glucose measurement per day, this regimen is cost-effective and easy to initiate. It’s decisive evidence for physicians to add basal insulin in patients failing oral therapy.”
In type 2 diabetes, control of blood glucose tends to worsen progressively over time, even with oral medications. Treatment with insulin, one of the most effective therapies to improve glycemic control, is often delayed due to fear of hypoglycemia; also once premixed insulin therapy is begun, oral medications are commonly discontinued.
“Insulin is a powerful treatment for achieving the kind of glycemic control that reduces diabetic complications for the millions of people with type 2 diabetes around the world, but too many patients remain at risk from poorly controlled blood glucose,” said Matthias-Axel Schweitzer, M.D., from the Medical Department of Aventis in Germany. “
The data was presented last week at the 40th Annual Meeting of the European Association for the Study of Diabetes in Munich, German
=======================

INSTANT A1c:
The In2it™ In-Office portable Analyzer delivers reimbursable laboratory-accurate A1C test results in less than seven minutes. It’s an easy, cost-efficient way to gauge the efficacy of your treatment strategies and make more informed treatment adjustments during the patient visit. For the cost of $8 dollars you can get printed results immediately. Studies have shown that having the A1c results when the patient is in the office, provides better diabetes control.
Learn More https://www.in2it-a1c.com